1108656-90-1

Usage

Uses

Since the provided materials do not specify the exact applications of N-Methylhex-5-en-1-amine 4-methylbenzenesulfonate, the following uses are hypothetical and based on the general properties of similar compounds:
Used in Pharmaceutical Industry:
N-Methylhex-5-en-1-amine 4-methylbenzenesulfonate could be used as an intermediate in the synthesis of pharmaceutical compounds for various therapeutic applications. Its amine and sulfonate groups may facilitate the formation of new chemical entities with potential medicinal properties.
Used in Chemical Synthesis:
In the chemical synthesis industry, N-Methylhex-5-en-1-amine 4-methylbenzenesulfonate may serve as a building block or reagent in the production of other organic compounds. Its functional groups could participate in various chemical reactions, such as nucleophilic substitution, addition, or condensation reactions.
Used in Material Science:
N-Methylhex-5-en-1-amine 4-methylbenzenesulfonate might be employed in the development of new materials with specific properties, such as polymers, coatings, or adhesives. Its amine and sulfonate groups could contribute to the desired characteristics of these materials, such as adhesion, solubility, or reactivity.

Upstream product

• 922520-05-6 2,2,2-trifluoro-N-(hex-5-enyl)-N-methylacetamide 
• 104-15-4 toluene-4-sulfonic acid 
• 2695-47-8 6-Bromo-1-hexene 

Downstream Products

• 1108657-00-6 C₃₅H₃₉N₃O₅ 
• 1265883-89-3 (1R,2R,4R)-5-(tert-butyldiphenylsilanyloxy)-2-(hex-5-enyl-methylcarbamoyl)cyclohexanecarboxylic acid tert-butyl ester 
• 1265882-93-6 (1R,2R,4R)-2-(hex-5-enylmethylcarbamoyl)-5-[7-methoxy-8-methyl-2-(4-trifluoromethylthiazol-2-yl)quinolin-4-yloxy]cyclohexane carboxylic acid benzyl ester 

Relevant academic research and scientific papers

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Phosphinate ruthenium complexes

Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.

MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula (Ia) or (Ib), pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.